It still takes 2 to Tango as Gilead triples targets in I-O deal now worth up to $6.2B Poseida shares plunge after death in solid tumor CAR-T trial, clinical hold Bad to worse for Applied Therapeutics as FDA slaps partial clinical hold on rare drug Sponsored: Why Ethical Procurement Matters for Human Biospecimens EU backs Big Pharma consortium to speed COVID-19 R&D Novo Nordisk taps Evotec to target chronic kidney disease Merck to build £1B London R&D hub for its first ex-U.S. early research center Kidney-focused Chinook to bank $106M ahead of Aduro merger close Swish: FDA greenlights 'game-changing' COVID-19 saliva test used by the NBA UCSF engineers develop llama-inspired 'AeroNabs' to strangle COVID-19 with an inhaler Featured Story | By Amirah Al Idrus Gilead Sciences and Tango Therapeutics hit the dance floor two years ago, with $50 million changing hands in a deal covering up to five immuno-oncology targets. Now, Gilead is ponying up another $125 million upfront, as well making a $20 million equity investment, to expand that deal to include up to 15 targets. read more |
| |
|---|
|
Top Stories By Ben Adams Poseida Therapeutics saw its shares plummet after-hours Monday when it revealed in a SEC filing that its cancer drug has been slapped with a full clinical hold. read more By Ben Adams The FDA has hit Applied Therapeutics with a partial clinical hold for its experimental galactosemia drug AT-007. read more By BioIVT While the response to COVID-19 and other disease indications drives science forward, regulatory guidelines that ensure the safe and ethical treatment of patients continues to be critically important. read more By Nick Paul Taylor A slate of Big Pharma companies led by Johnson & Johnson and Takeda has allied with research centers to advance COVID-19 drugs. The EU-backed, 37-member initiative is seeking to reposition existing drugs and develop novel small molecules and virus-neutralizing antibodies. read more By Nick Paul Taylor Novo Nordisk has signed up to work with Evotec on the discovery and development of chronic kidney disease drugs. The deal comes two years after Novo Nordisk licensed a kidney disease prospect from Epigen Biosciences as part of its effort to expand into areas adjacent to its core diabetes business. read more By Ben Adams Making good on its 2017 promise to back post-Brexit Britain, U.S. Big Pharma Merck is set to spend £1 billion ($1.31 billion) on a new unifying early research hub in England’s capital city. read more By Amirah Al Idrus Just two months after merging its way onto the Nasdaq, Chinook Therapeutics is at it again. The kidney-focused biotech plans to raise $106 million in a private round that will push a trio of assets through the clinic and gear up for the expected approval and launch of its lead program, an endothelin receptor antagonist. read more By Conor Hale The rapid, saliva-based coronavirus test used to screen NBA players within “the bubble” as they work through their current basketball season has now been authorized by the FDA for use across the country. read more By Arlene Weintraub UCSF researchers engineered a three-part antibody chain to block COVID-19 that's inspired by the tiny nanobodies that llamas and other camelids make naturally to fight off pathogens. They believe the treatment could be delivered as an aerosol and used as a self-administered form of protection against the virus. read more Enrollment Showcase | Presented by: Biotility Taught by experienced professionals, Biotility’s online short courses provide the knowledge and practical skills valued by the bioscience industry. Enhance your career through coursework in one of our certificate pathways, including Document Management, Operations Management, and Quality Management. Learn more. |
| |
|---|
|
Resources Sponsored by: Oracle Health Sciences Patient-facing digital technologies are playing an important role in clinical trials for new drugs and medical devices, to the point where conducting virtual trials is becoming mainstream. But terms like remote trials, direct-to-patient trials, hybrid trials, decentralized trials, and more all add to the confusion of what makes a trial "virtual." Sponsored by: Oracle Health Sciences The research conducted here is to help understand and solve the top challenges in clinical operations, to remove barriers that are slowing down our ability to bring new drugs to market as quickly as possible to patients waiting in need. Sponsored by: Thermo Fisher Scientific How to select the right dosage form for your Phase I clinical supply. Sponsored by: Thermo Fisher Scientific Quality by Design (QbD) reduces risk within drug development, while bringing therapies to market quicker. Sponsored by: Evotec Two informative webcasts will present practical and methodological approaches to preclinical drug abuse liability assessment Sponsored by: Catalent Pharmaceutical and biotech companies are spending years developing drugs or promising new biologics, all with the hopes of saving or enhancing patients’ lives. It’s a “race to the finish” in some cases, and the quicker a company can get its product to patients, the better. Sponsored by: Acorn AI by Medidata, a Dassault Systèmes company Case Study: Oncology-focused pharmaceutical company strengthens product launch by identifying hundreds of high-value physicians with Acorn AI. Sponsored by: Paysign Download the whitepaper for a solution designed to connect manufacturers, pharmacists, and patients. In this special guide, you will learn not just about the law but about the portal platform designed to change the entire process for all. Sponsored by: Cardinal Health 3PL Services Identifying opportunities to simplify channel strategies and business processes for biopharma companies, their customers and patients. Sponsored by: Catalent In a BioPharma Dive industry survey, planning and forecasting were identified as top concerns for trial sponsors. In response to this need, the CSM team at Catalent has developed a methodology for identifying, evaluating, and proactively managing the inherent risks involved in clinical trial supply chain management. Sponsored by: PRA Health Sciences Drug developers and stakeholders must find ways to collaborate, rather than compete, as the RACE Act prompts the need for more pediatric research. Sponsored by: Catalent Learn about a real-world example of how clinical supply management expertise was applied to overcome inventory challenges for a complex, global study. Sponsored by: Catalent Whether a study is simple or highly complex, forecasting and simulation reports serve as data driven communication tools to help minimize risks and keep the study on track. Learn more about forecasting solutions for informed decision making and supporting contingency planning for clinical study. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. Why Your Business Needs a Ransomware Strategy To Avoid Being Hacked! N/A Drug Development Boot Camp® 2020 November 18-19, 2020 | Register now! Pre-Boot Camp training ongoing now. | COVID19 provisions – training will be on-site as normal. | New – may be possible for some individuals to access the training virtually in real time. | 